血清microRNA-760-3p和血管内皮钙黏蛋白预测冠心病患者抗血小板治疗的出血风险

关欣; 杨平; 柳江海

doi:10.13201/j.issn.1001-1439.2025.02.006

血清microRNA-760-3p和血管内皮钙黏蛋白预测冠心病患者抗血小板治疗的出血风险

- 1.
  西安工会医院心血管内二科(西安，710100)
- 2.
  宝鸡市人民医院
- 3.
  厦门大学附属心血管病医院

详细信息

通讯作者: 柳江海，E-mail：liujianghai0902@163.com

中图分类号: R541.4

收稿日期: 2024-09-11

刊出日期: 2025-02-13

Serum miR-760-3p and VE-cadherin predict bleeding risk in patients with coronary heart disease treated with antiplatelet therapy

- 1.
  Department of Cardiology, Xi'an Trade Union Hospital, Xi'an, 710100, China
- 2.
  Baoji People's Hospital
- 3.
  Cardiovascular Hospital Affiliated to Xiamen University

More Information

Corresponding author: LIU Jianghai, E-mail: liujianghai0902@163.com

Received Date: 11 September 2024

Publish Date: 13 February 2025

摘要

摘要: 目的探讨血清microRNA(miR)-760-3p和血管内皮钙黏蛋白(VE-cadherin)水平预测冠心病(CHD)患者抗血小板治疗出血风险的价值。方法本研究纳入了214例于2021年1月—2023年8月接受抗血小板治疗的CHD患者。根据随访期间是否发生出血事件，将患者分为出血组(33例)和非出血组(181例)。通过qRT-PCR、ELISA检测两组患者的血清miR-760-3p和VE-cadherin水平，比较两组间的差异。使用logistic回归分析评估miR-760-3p和VE-cadherin水平与出血事件之间的关系，并通过ROC曲线分析其预测能力。结果在214例患者中，出血事件发生率为15.42%。出血组的miR-760-3p和VE-cadherin水平显著高于非出血组(P<0.05)。Logistic回归分析显示，miR-760-3p(OR=2.231，95%CI 1.254~4.002)和VE-cadherin(OR=1.570，95%CI 1.043~2.363)水平是出血事件发生的影响因素(P<0.05)。ROC曲线显示，血清miR-760-3p和VE-cadherin联合预测CHD患者抗血小板治疗出血风险的AUC为0.823，较两指标单独预测的价值高(P<0.05)。结论高表达的miR-760-3p和VE-cadherin与出血风险显著相关，其联合检测有助于预测CHD抗血小板治疗后出血风险。
- microRNA-760-3p /
- 血管内皮钙黏蛋白 /
- 抗血小板 /
- 出血风险
Abstract: Objective To explore the value of serum miR-760-3p and vascular endothelial cadherin(VE-cadherin) levels in predicting the bleeding risk of patients with coronary heart disease(CHD) treated with antiplatelet therapy.Methods This study included 214 CHD patients who received antiplatelet therapy from January 2021 to August 2023. According to whether bleeding events occurred during follow-up, patients were divided into bleeding group(33 cases) and non-bleeding group(181 cases). The serum levels of miR-760-3p and VE-cadherin in the two groups of patients were detected by qRT-PCR and ELISA, and the differences between the two groups were compared. Logistic regression analysis was used to evaluate the relationship between miR-760-3p and VE-cadherin levels and the incidence of bleeding events, and their predictive ability was analyzed by ROC curve.Results Among 214 patients, the incidence rate of bleeding events was 15.42%. qRT-PCR and ELISA test results showed that the levels of miR-760-3p and VE-cadherin in the bleeding group were significantly lower than those in the non-bleeding group(P<0.05). Logistic regression analysis showed that the levels of miR-760-3p and VE-cadherin were significantly related to the occurrence of bleeding events(P<0.05). The OR of miR-760-3p was 2.231(95%CI: 1.254-4.002), and the OR of VE-cadherin was 1.570(95%CI: 1.043-2.363). The ROC curve showed that the AUC of serum miR-760-3p and VE-cadherin in predicting the bleeding risk of antiplatelet therapy in CHD patients was 0.823, which was higher than that predicted by the two indicators alone(P<0.05), indicating that the combination of the two had better predictive power.Conclusion Serum miR-760-3p and VE-cadherin levels can be used as potential biomarkers to predict the risk of bleeding during antiplatelet therapy in patients with CHD. High expression of miR-760-3p and VE-cadherin are significantly associated with bleeding risk.
- microRNA-760-3p /
- VE-cadherin /
- antiplatelet /
- bleeding risk

HTML全文

图 1 血清miR-760-3p和VE-cadherin预测CHD患者抗血小板治疗出血风险的ROC曲线

Figure 1. ROC curves

下载: 全尺寸图片幻灯片

表 1 两组临床资料的比较

Table 1. General data 例(%), X±S

临床特征	出血组(33例)	非出血组(181例)	χ²/t	P
年龄/岁	68.23±10.51	66.75±9.84	0.786	0.432
男性	21(63.64)	118(65.19)	0.334	0.863
高血压	25(75.76)	132(72.93)	0.563	0.701
糖尿病	14(42.42)	65(35.91)	0.741	0.468
血脂异常	20(60.61)	101(55.80)	0.467	0.618
吸烟史	16(48.48)	83(45.86)	0.543	0.778
BMI/(kg/m²)	27.45 ±3.13	26.93±3.06	0.895	0.372

下载: 导出CSV

表 2 两组miR-760-3p和VE-cadherin水平比较

Table 2. miR-760-3p and VE-cadherin X±S

指标	出血组(33例)	非出血组(181例)	t	P
miR-760-3p	3.45±0.92	2.88±0.76	3.830	<0.05
VE-cadherin/(ng/mL)	8.72±2.14	6.54 ± 1.89	5.968	<0.05

下载: 导出CSV

表 3 Logistic回归分析出血事件与miR-760-3p和VE-cadherin的关系

Table 3. Logistic regression analysis

指标	B	SE	Wald	自由度	P	OR	95%CI
miR-760-3p	0.8	0.3	7.23	1	0.007	2.231	1.254~4.002
VE-cadherin	0.45	0.22	4.56	1	0.033	1.570	1.043~2.363

下载: 导出CSV

表 4 血清miR-760-3p和VE-cadherin预测CHD患者抗血小板治疗出血风险的价值

Table 4. The value of serum miR-760-3p and VE cadherin in predicting the bleeding risk of antiplatelet therapy in CHD patients

检测指标	AUC	S.E.	95%CI	特异度	灵敏度	P
miR-760-3p	0.731	0.039	0.654~0.808	0.652	0.801	<0.05
VE-cadherin	0.815	0.042	0.733~0.897	0.715	0.822	<0.05
联合	0.823	0.039	0.747~0.899	0.812	0.843	<0.05

下载: 导出CSV

参考文献(16)

[1]	李文慧, 周双, 向倩. 抗血小板治疗策略对于经皮冠状动脉介入术预后影响的研究现状[J]. 中国临床药理学杂志, 2023, 39(10): 1490-1494.
[2]	Wang Y, Niu HC, Li LY, et al. Anti-CHAC1 exosomes for nose-to-brain delivery of miR-760-3p in cerebral ischemia/reperfusion injury mice inhibiting neuron ferroptosis[J]. J Nanobiotechnology, 2023, 21(1): 109. doi: 10.1186/s12951-023-01862-x
[3]	Zhang H, Deng J, Huang KL, et al. circNup188/miR-760-3p/Map3k8 axis regulates inflammation in cerebral ischemia[J]. Mol Cell Probes, 2022, 64: 101830. doi: 10.1016/j.mcp.2022.101830
[4]	杨逢永, 房东东, 张柄涵, 等. 盐酸戊乙奎醚调控血管生成素2/血管内皮钙黏蛋白(Ang2/VE-cadherin)通路减轻脂多糖诱导的大鼠肺损伤[J]. 细胞与分子免疫学杂志, 2023, 39(8): 708-713.
[5]	Roncalli J, Godin M, Boughalem K, et al. Paclitaxel drug-coated balloon after bare-metal stent implantation, an alternative treatment to drug-eluting stent in high bleeding risk patients(the panelux trial)[J]. J Invasive Cardiol, 2019, 31(4): 94-100.
[6]	Hicks KA, Stockbridge NL, Targum SL, et al. Bleeding academic research consortium consensus report: the food and drug administration perspective[J]. Circulation, 2011, 123(23): 2664-2665. doi: 10.1161/CIRCULATIONAHA.111.032433
[7]	袁祖贻, 肖懿慧. 急性冠状动脉综合征抗血小板降阶治疗策略的研究进展[J]. 临床心血管病杂志, 2022, 38(10): 767-770. doi: 10.13201/j.issn.1001-1439.2022.10.001
[8]	陈桤璐, 卢志贤, 刘敏, 等. 血清hs-cTnT、PCT、FIB与血小板聚集率在冠心病中的表达及意义[J]. 临床血液学杂志, 2023, 36(12): 873-877.
[9]	Chen B, Tan L, Wang Y, et al. LOC102549726/miR-760-3p network is involved in the progression of ISO-induced pathological cardiomyocyte hypertrophy via endoplasmic reticulum stress[J]. J Mol Histol, 2023, 54(6): 675-687. doi: 10.1007/s10735-023-10166-1
[10]	Harris NR, Nielsen NR, Pawlak JB, et al. VE-cadherin is required for cardiac lymphatic maintenance and signaling[J]. Circ Res, 2022, 130(1): 5-23. doi: 10.1161/CIRCRESAHA.121.318852
[11]	Wang Y, Yu Z, Cheng MH, et al. Buyang Huanwu decoction promotes remyelination via miR-760-3p/GPR17 axis after intracerebral hemorrhage[J]. J Ethnopharmacol, 2024, 328: 118126. doi: 10.1016/j.jep.2024.118126
[12]	陶晓芳, 王雅洁, 王文斌, 等. MiR-182调控线粒体凋亡通路对冠心病模型大鼠心肌组织细胞凋亡的影响[J]. 中国老年学杂志, 2024, 44(3): 662-665. doi: 10.3969/j.issn.1005-9202.2024.03.038
[13]	Grimsley-Myers CM, Isaacson RH, Cadwell CM, et al. VE-cadherin endocytosis controls vascular integrity and patterning during development[J]. J Cell Biol, 2020, 219(5): e201909081. doi: 10.1083/jcb.201909081
[14]	Delgado-Bellido D, Zamudio-Martínez E, Fernández-Cortés M, et al. VE-Cadherin modulates β-catenin/TCF-4 to enhance Vasculogenic Mimicry[J]. Cell Death Dis, 2023, 14(2): 135. doi: 10.1038/s41419-023-05666-7
[15]	Yang K, Fan M, Wang XH, et al. Lactate induces vascular permeability via disruption of VE-cadherin in endothelial cells during sepsis[J]. Sci Adv, 2022, 8(17): eabm8965. doi: 10.1126/sciadv.abm8965
[16]	Delgado-Bellido D, Oliver FJ, Vargas Padilla MV, et al. VE-cadherin in cancer-associated angiogenesis: a deceptive strategy of blood vessel formation[J]. Int J Mol Sci, 2023, 24(11): 9343. doi: 10.3390/ijms24119343